Full Agonist Therapy (Methadone): Methadone fully activates the mu-opioid receptors. It is highly effective for patients with high levels of physical dependence because it completely suppresses withdrawal and cravings when dosed correctly.
Partial Agonist Therapy (Buprenorphine): Buprenorphine activates receptors only partially, which provides a 'ceiling effect' on respiratory depression and euphoria. This makes it safer in overdose scenarios and allows for office-based prescriptions.
Antagonist Therapy (Naltrexone): Naltrexone blocks opioid receptors entirely. If a patient uses an opioid while on Naltrexone, they will feel no effect, effectively breaking the behavioral reinforcement cycle of drug use.
| Feature | Full Agonist (Methadone) | Partial Agonist (Buprenorphine) | Antagonist (Naltrexone) |
|---|---|---|---|
| Mechanism | Full activation | Partial activation | Complete blockade |
| Withdrawal | Prevents withdrawal | Prevents withdrawal | Does NOT prevent withdrawal |
| Abuse Potential | Higher | Lower (Ceiling effect) | None |
| Setting | Specialized clinics | Office-based/Pharmacy | Office-based |
'Trading One Addiction for Another': A common misconception is that medication-assisted treatment (MAT) is just replacing one drug with another. In reality, MAT replaces a dangerous, short-acting illicit drug with a stable, long-acting medication that allows for normal social and occupational functioning.
Medication as a Standalone Cure: Pharmacotherapy is most effective when combined with behavioral therapies. Relying solely on the drug without addressing the psychological aspects of addiction often leads to poorer long-term outcomes.
Under-dosing: Providing a dose that is too low to suppress cravings can lead to treatment failure. Clinical success requires 'blocking doses' that effectively saturate receptors.